ERI HIROFUJI: Open Payments
NPI 1184099335 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 16 payments from 8 companies in 2025. Trend: 2023 $562 · 2024 $772 · 2025 $560
Food & beverage: $460Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $274 |
| Astellas Pharma US Inc | 1 | $100 |
| AstraZeneca Pharmaceuticals LP | 2 | $57 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| Celgene Corporation | 1 | $28 |
| Geron Corporation | 1 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| SOBI, INC | 1 | $20 |
Products named: RYBREVANT, CARVYKTI, TALVEY, CALQUENCE, BLENREP, REBLOZYL, RYTELO, TAVALISSE.
Industry payments across CA — which companies pay providers there.
